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Comorbid conditions appear to be common among individuals hospitalised with coronavirus
disease 2019 (COVID-19) but estimates of prevalence vary and little is known about the prior
medication use of patients. Here, we describe the characteristics of adults hospitalised with
COVID-19 and compare them with influenza patients. We include 34,128 (US: 8362, South
Korea: 7341, Spain: 18,425) COVID-19 patients, summarising between 4811 and 11,643
unique aggregate characteristics. COVID-19 patients have been majority male in the US and
Spain, but predominantly female in South Korea. Age profiles vary across data sources.
Compared to 84,585 individuals hospitalised with influenza in 2014-19, COVID-19 patients
have more typically been male, younger, and with fewer comorbidities and lower medication
use. While protecting groups vulnerable to influenza is likely a useful starting point in the
response to COVID-19, strategies will likely need to be broadened to reflect the particular
characteristics of individuals being hospitalised with COVID-19.
https://doi.org/10.1038/s41467-020-18849-z OPEN
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The ongoing coronavirus disease 2019 (COVID-19) pan-demic is placing a huge strain on health systems world-wide. While a number of studies have provided
information on the clinical characteristics of individuals being
hospitalised with COVID-191–3, substantial uncertainty around
the prevalence of comorbidities and prior medication use among
this population remains. Moreover, it is not known whether those
hospitalised with COVID-19 are systematically different from
individuals hospitalised during previous influenza seasons.
COVID-19 shares similarities with influenza to the extent that
both cause respiratory disease which can vary markedly in its
severity and present with a similar constellation of symptoms,
including fever, cough, myalgia, malaise, fatigue and dyspnoea.
Early reports do, however, indicate that the proportion of severe
infections and mortality rate is higher for COVID-194. Older age
and a range of underlying health conditions, such as immune
deficiency, cardiovascular disease, chronic lung disease, neuro-
muscular disease, neurological disease, chronic renal disease and
metabolic diseases, have been associated with an increased risk of
severe influenza and associated mortality5. While age appears to
be a clear risk factor for severe COVID-194, other associations are
not yet well understood. Comparisons with COVID-19 are fur-
ther complicated by the heterogeneity in influenza itself, with
different strains resulting in different clinical presentations and
associated risks. Those hospitalised with the A(H1N1)
pdm09 subtype of the influenza A virus during the associated
influenza pandemic in 2009 were, for example, generally younger
and with fewer comorbidities than those from preceding influ-
enza seasons6.
Here we first aimed to describe the characteristics of patients
hospitalised with COVID-19. In particular, we set out to sum-
marise individuals’ demographics, medical conditions, and
medication use. Our second aim was to compare the character-
istics of individuals hospitalised with COVID-19 to those of
patients hospitalised with influenza in previous seasons.
Results
Patients hospitalised with COVID-19. A total of 34,128 indivi-
duals hospitalised with COVID-19 (CUIMC: 1759; HIRA: 7341;
HM: 2078; PHD: 5257; SIDIAP: 16,347; UC HDC: 769; VA
OMOP: 577) were included. In all, 68,829 summary character-
istics, from 4811 (HM) to 11,643 (CUIMC) unique aggregate
characteristics, were extracted and summarised. All are made
available in an accompanying interactive website (http://evidence.
ohdsi.org/Covid19CharacterizationHospitalization/).
Cohorts from CUIMC, HM, PHD, SIDIAP, UC HDC and VA
OMOP were predominantly male (52%, 60%, 52%, 54%, 54% and
94%, respectively, but mostly female for HIRA (60%). The age
distributions of those hospitalised for COVID-19 are summarised
in Fig. 1 (alongside those hospitalised with influenza, see below).
Different patterns are seen in the various contributing databases
with, in particular, patients in South Korea (HIRA) seen to be
younger than elsewhere.
The distribution of comorbidities in COVID-19 patients varied
across sites and countries, see Table 1. The mean Charlson
comorbidity index of those hospitalised with COVID-19 in the
US ranged from 3.1 for PHD to 5.4 for VA OMOP, from 0.8 for
HM to 1.4 for SIDIAP in Spain, and was 2.7 in HIRA, covering
South Korea. In the US, the proportion of those hospitalised with
COVID-19 who had asthma ranged from 7 to 15%, from 24 to
43% for diabetes, from 28 to 49% for heart disease and from 8 to
18% for cancer. In Spain, between 4 and 7% for asthma, from 13
to 22% for diabetes, from 17 to 27% for heart disease and from 5
to 16% for cancer. In South Korea, 12% of those hospitalised had
a history of asthma, 17% had diabetes, 13% heart disease and 4%
cancer. The prevalence of hypertension ranged from 37 to 70% in
the US, from 30 to 46% in Spain and was 24% in South Korea.
The prevalence of the full range of conditions summarised are
shown in Fig. 2, with all values reported at http://evidence.ohdsi.
org/Covid19CharacterizationHospitalization/.
For medications, the proportion of those hospitalised with
COVID-19 in the US who had been taking agents acting on the
renin–angiotensin system over the 30 days up to their hospitalisa-
tion ranged from 18% to 39%, while the proportions taking
immunosuppressants ranged from 4 to 6%, and from 21 to 51% for
lipid-modifying agents over the same time period. In HIRA, 14%
had been taking agents acting on the renin–angiotensin system, 1%
immunosuppressants, and 16% lipid-modifying agents. In SIDIAP,
27% had been taking agents acting on the renin–angiotensin
system, 2% immunosuppressants, and 24% lipid-modifying agents
(Table 2). Looking at one medication of particular interest (of which
many can be explored in detail at http://evidence.ohdsi.org/
Covid19CharacterizationHospitalization/), use of hydroxychloro-
quine on the day of admission was 7% in HIRA and 41% in HM.
The prevalence of the many medications summarised are shown in
Fig. 2, with all values reported http://evidence.ohdsi.org/
Covid19CharacterizationHospitalization/.
Removing the requirement of having a year prior history in
datasets other than HM and Premier did not materially change
the results (see http://evidence.ohdsi.org/Covid19Characteriza-
tionHospitalization/ for full details).
A comparison of patients hospitalised with COVID-19 and
patients hospitalised with influenza. A total of 84,585 patients
hospitalised with influenza between 2014 and 2019 (2125
CUIMC, 49,977 PHD, 2947 SIDIAP, UC HDC 26,547 VA
OMOP). In addition, 2443 patients hospitalised with influenza
between 2009 to 2010 were included (170 CUIMC, 1689 SIDIAP,
584 VA OMOP) were also identified. Patient characteristics of
those hospitalised with COVID-19 are compared to those of
individuals hospitalised with influenza between 2014 and 2019 in
Figs. 1, 3 and 4, and with those hospitalised with influenza
between 2009 and 2010 in Supplementary Fig. 1 and Supple-
mentary Fig. 2.
A greater proportion of those hospitalised with COVID-19
were male compared to those hospitalised with influenza between
2014 and 2019 for CUIMC, PHD, SIDIAP and UC HDC. Of
those hospitalised between 2014 and 2019 with influenza 43, 44,
53 and 45% were male for each of these respective data sources.
The ages of those hospitalised with COVID-19 generally appeared
slightly younger compared to those hospitalised with influenza
between 2014 and 2019, see Fig. 1.
Those hospitalised with COVID-19 had a comparable or
lower prevalence of comorbidities compared to those hospita-
lised with influenza 2014–2019 (see Fig. 3 top and Fig. 4).
Chronic obstructive pulmonary disease (COPD), cardiovascular
disease and dementia were all more common amongst those
hospitalised with influenza compared to those hospitalised with
COVID-19. Medication use was less common amongst
COVID-19 patients (Fig. 3 bottom and Fig. 4) with, for
example, systemic corticosteroids and alpha-blockers amongst
those more frequently used among those hospitalised with
influenza.
Those hospitalised with influenza between 2009 and 2010 were
typically younger compared to both COVID-19 and to influenza
2014–2019 admissions (see Supplementary Fig. 1 and Supple-
mentary Table 2). COVID-19 patients were more likely to be
male, with 40, 49 and 91% of those hospitalised between 2009 and
2010 for influenza being male for CUIMC, SIDIAP and VA
OMOP. Comparisons of conditions and medications, however,
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varied depending on the data source (see Supplementary Fig. 4
and Supplementary Table 2).
Discussion
Summary of key findings. The characteristics of 34,128 patients
hospitalised with COVID-19 in US, South Korea, and Spain have
been extracted from EHRs and health claims databases and
summarised. Between 5000 and 12,000 unique aggregate char-
acteristics have been produced across databases, with all made
publicly available in an accompanying website.
Patients hospitalised with COVID-19 in the US and Spain were
predominantly male with age distributions varying across data
sources, while those in South Korea were mostly female and
appreciably younger than patients in the US and Spain. Many
comorbidities were common among individuals hospitalised with
COVID-19 with, as an example, 37–70% of those hospitalised
with COVID-19 in the US, 30–46% of those in Spain and 24% of
those in South Korea having hypertension. Similarly, prior
medication use was common with, for example, 18–39% in the
US, 27% in Spain and 14% in South Korea, taking drugs acting on
the renin–angiotensin system (ACE inhibitors and ARBs) in the
30 days up to their hospitalisation.
Comparisons with previous cohorts of patients admitted to
hospital for seasonal influenza in recent years suggest that
COVID-19-related admissions are seen more often in younger
patients and with a higher proportion of men. In the US and
Spain, those hospitalised with COVID-19 were generally either of
comparable health or healthier than patients hospitalised with
influenza. Consistent differences were noted in the prevalence of
respiratory disease, cardiovascular disease and dementia, each
more common amongst those hospitalised with influenza in all of
the contributing databases. Similarly, the use of corticosteroids
and alpha-blockers was consistently higher amongst influenza
patients. Those hospitalised with influenza in 2009–2010, during
the pandemic associated with H1N1, were seen to be younger
than both those hospitalised with influenza in more recent years
and patients hospitalised with COVID-19.
Findings in context. A number of studies have previously pro-
vided information on individuals hospitalised with COVID-19.
While cohorts have generally been majority male, the prevalence
of comorbidities has varied. In a study of 1099 individuals who
tested positive for COVID-19 in China, of whom 94% were
hospitalised, 58% were male, with 7% having diabetes, 15%
hypertension and 1% cancer7. In another study of 191 patients
with COVID-19 in two hospitals in Wuhan, China, 62% were
male, 19% had diabetes, 30% had hypertension and 1% had
cancer8. In a study which identified 1999 individuals who tested
positive for COVID-19 and were hospitalised in New York, 63%
were male, 25% had diabetes, 10% COPD and 45% a cardiovas-
cular condition9. In another US study of 1482 patients admitted
to hospital with COVID-19 in March 2020, 55% were male, with
28% having diabetes, 11% having COPD and 28% having cardi-
ovascular disease10. Our findings add to this emerging body of
evidence. The results from our study also provide an illustration
of the variation in patient characteristics across contexts, with
heterogeneity seen both across the cohorts from the US and
between the US, Spain and South Korea.
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(n: 1759 COVID-19, 2125 Influenza)
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(n: 5257 COVID-19, 49,977 Influenza)
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(n: 16,347 COVID-19, 2947 Influenza)
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(n: 769 COVID-19, 2989 Influenza)
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(n: 577 COVID-19, 26,547 Influenza)
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Fig. 1 Age of patients hospitalised with COVID-19 and of patients hospitalised with influenza. Individuals hospitalised with COVID-19 between
December 2019 and April 2020 compared with those hospitalised with influenza between September 2014 to April 2019 (where available). Proportion of
cohorts by 5-year age groups, with groups with counts of <10 omitted. CUIMC: Columbia University Irving Medical Center; HIRA: Health Insurance Review
& Assessment; HM: HM Hospitales; PHD: Premier Healthcare Database; SIDIAP: The Information System for Research in Primary Care; UC HDC:
University of Colorado Health Data Compass; VA OMOP: Department of Veterans Affairs. Influenza data for SIDIAP was only available from 2014 to 2017.
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The comparison with influenza made in our study adds
important context when considering the characteristics of those
hospitalised with COVID-19. Individuals hospitalised with
COVID-19 appear to be more likely younger and male, and in
the United States and Spain, to have fewer comorbidities than
those hospitalised with influenza in previous years. Indeed, those
Table 1 Conditions of individuals hospitalised with COVID-19.
CUIMC
(n: 1759)
HIRA
(n: 7341)
HM (n: 2078) PHD
(n: 5257)
SIDIAP (n:
16,347)
UC HDC
(n: 769)
VA OMOP
(n: 577)
Charlson index 4.0 2.0 0.8 3.1 1.5 3.5 5.4
Anaemia 13.1% 11.9% 4.2% 30.2% 14.6% 29.9% 30.0%
Anxiety disorder 5.5% 11.5% 2.3% 18.0% 23.7% 18.2% 30.3%
Asthma 7.2% 12.0% 4.2% 14.6% 6.9% 13.8% 9.9%
Atrial fibrillation 8.4% 1.0% 6.8% 18.1% 8.2% 12.0% 15.8%
Chronic liver disease 2.6% 5.0% 0.6% 3.0% 1.9% 2.3% 6.8%
COPD 6.1% 1.9% 5.9% 24.5% 7.6% 12.6% 28.6%
Dementia 8.5% 5.3% 2.3% 9.2% 5.6% 7.4% 7.8%
Diabetes mellitus 24.2% 16.6% 13.2% 35.8% 21.6% 35.2% 43.3%
GERD 9.6% 32.3% 1.6% 24.8% 9.5% 23.4% 26.9%
Heart disease 28.3% 13.1% 16.5% 48.6% 27.1% 39.0% 48.2%
Heart failure 10.7% 5.1% 2.7% 24.8% 5.9% 12.9% 22.2%
Hyperlipidemia 24.7% 31.1% 21.3% 46.0% 23.7% 38.0% 55.8%
Hypertensive disorder 36.6% 23.8% 29.6% 47.1% 45.6% 57.3% 69.7%
Insomnia 3.1% 4.2% 0.7% 4.4% 14.6% 7.4% 10.9%
Ischaemic heart disease 8.0% 6.9% 4.1% 16.0% 7.3% 13.5% 15.6%
Low back pain 6.8% 23.2% <0.5% 5.0% 21.9% 11.1% 30.0%
Malignant neoplastic disease 7.7% 4.4% 4.5% 9.4% 15.8% 10.8% 18.4%
Osteoarthritis of knee 4.6% 7.7% <0.5% 2.0% 14.8% 5.1% 11.4%
Osteoarthritis of hip 3.0% 0.5% <0.5% 1.1% 5.1% 2.6% 2.8%
Peripheral vascular disease 4.7% 8.0% 0.5% 7.5% 3.9% 7.4% 10.6%
Renal impairment 21.1% 1.8% 7.6% 37.5% 13.1% 37.2% 32.9%
Venous thrombosis 2.3% 0.6% 0.8% 2.0% 1.5% 6.6% 4.0%
Viral hepatitis 2.3% 3.9% 0.6% 2.5% 1.7% 2.6% 5.9%
Exact proportions have not been reported where counts were <10. Conditions were identified over the year prior and up to, and including, day of hospitalisation (note, HM and PHD had no prior time
requirement with conditions primarily recorded on the day of hospital admission).
CUIMC Columbia University Irving Medical Center, HIRA Health Insurance Review & Assessment, HM HM Hospitales, PHD Premier Healthcare Database, SIDIAP The Information System for Research in
Primary Care, UC HDC University of Colorado Health Data Compass, VA OMOP Department of Veterans Affairs, COPD chronic obstructive pulmonary disease, GERD gastroesophageal reflux disease.
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Fig. 2 Prevalence of conditions and medication use among COVID-19 patients. Individuals hospitalised with COVID-19 between December 2019 and
April 2020. Conditions from up to a year prior, medication use from day of hospitalisation. Each dot represents one of these covariates with the colour
indicating the type of condition/medication. CUIMC: Columbia University Irving Medical Center; HIRA: Health Insurance Review & Assessment; HM: HM
Hospitales; PHD: Premier Healthcare Database; SIDIAP: The Information System for Research in Primary Care; UC HDC: University of Colorado Health
Data Compass; VA OMOP: Department of Veterans Affairs.
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Table 2 Prior medications of individuals hospitalised with COVID-19.
CUIMC
(n: 1759)
HIRA
(n: 7341)
HM (n: 2078) PHD
(n: 5257)
SIDIAP (n:
16,347)
UC HDC
(n: 769)
VA OMOP
(n: 577)
Antineoplastic and immunomodulating agents
Year up to, and including day
of, hospitalisation
9.6% 4.5% – – 3.4% 12.9% 13.2%
30 days up to, and including
day of, hospitalisation
6.1% 2.6% – – 2.7% 9.6% 7.1%
Day of hospitalisation 4.9% 2.0% 3.8% 2.1% 2.5% 8.2% 4.9%
Agents acting on the renin–angiotensin system
Year up to, and including day
of, hospitalisation
27.3% 15.9% – – 30.2% 39.8% 49.6%
30 days up to, and including
day of, hospitalisation
18.0% 14.2% – – 26.6% 33.0% 38.5%
Day of hospitalisation 15.9% 13.4% 9.9% 7.4% 25.7% 31.5% 33.1%
Antiepileptics
Year up to, and including day
of, hospitalisation
19.0% 9.1% – – 10.6% 27.2% 33.4%
30 days up to, and including
day of, hospitalisation
9.9% 5.2% – – 8.1% 21.6% 22.7%
Day of hospitalisation 9.1% 4.2% 3.3% 11.3% 7.7% 20.2% 16.6%
Anti-inflammatory and antirheumatic products
Year up to, and including day
of, hospitalisation
23.6% 63.9% – – 30.9% 52.9% 46.1%
30 days up to, and including
day of, hospitalisation
10.5% 30.0% – – 9.9% 38.6% 16.8%
Day of hospitalisation 7.8% 17.7% 3.8% 7.9% 6.3% 35.1% 9.9%
Antithrombotic agents
Year up to, and including day
of, hospitalisation
44.9% 34.6% – – 25.7% 72.0% 46.1%
30 days up to, and including
day of, hospitalisation
29.9% 17.1% – – 21.9% 67.5% 16.8%
Day of hospitalisation 28.3% 11.4% 38.2% 38.4% 21.3% 66.8% 9.9%
Beta-blocking agents
Year up to, and including day
of, hospitalisation
26.9% 10.1% – – 13.8% 32.8% 44.4%
30 days up to, and including
day of, hospitalisation
16.8% 6.5% – – 12.4% 24.7% 36.0%
Day of hospitalisation 15.2% 5.6% 5.7% 17.8% 11.9% 23.8% 31.0%
Calcium channel blockers
Year up to, and including day
of, hospitalisation
23.5% 16.7% – – 12.4% 24.3% 35.0%
30 days up to, and including
day of, hospitalisation
15.0% 14.6% – – 10.5% 20.5% 27.0%
Day of hospitalisation 13.4% 14.0% 6.8% 9.7% 10.1% 19.9% 24.3%
Diuretics
Year up to, and including day
of, hospitalisation
27.6% 10.2% – – 24.6% 33.3% 42.6%
30 days up to, and including
day of, hospitalisation
19.2% 7.5% – – 21.5% 27.4% 33.1%
Day of hospitalisation 17.7% 6.7% 7.6% 14.1% 20.7% 26.4% 28.4%
Drugs for acid related disorders
Year up to, and including day
of, hospitalisation
35.4% 68.8% – – 30.4% 53.6% 52.0%
30 days up to, and including
day of, hospitalisation
20.6% 36.5% – – 22.7% 44.5% 36.2%
Day of hospitalisation 17.9% 29.3% 39.7% 21.8% 21.5% 42.4% 28.9%
Immunosuppressants
Year up to, and including day
of, hospitalisation
5.6% 2.0% – – 2.3% 7.5% 5.7%
30 days up to, and including
day of, hospitalisation
3.9% 0.7% – – 1.9% 6.1% 3.5%
Day of hospitalisation 3.7% 0.4% 2.5% 1.5% 1.7% 5.9% 2.6%
Insulins and analogues
Year up to, and including day
of, hospitalisation
17.8% 3.7% – – 5.5% 31.9% 22.9%
30 days up to, and including
day of, hospitalisation
10.9% 2.7% – – 4.9% 26.9% 18.4%
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hospitalised with COVID-19 were consistently seen to be less
likely to have COPD, cardiovascular disease and dementia than
those hospitalised with influenza in recent years.
This study has also added important information on medica-
tion use by individuals hospitalised with COVID-19, based on
electronic health records and claims data. There is tremendous
interest in the risks and benefits of medications such as ACE
inhibitors and ARBs for COVID-19, and whether other
medications, such as ibuprofen, should be avoided. However, to
date, there has been little evidence as to what proportion of those
hospitalised with COVID-19 have previously been taking such
medications. Our findings shed light on this area, and highlight
the importance of further research on the benefits and harms
associated with continued use of such treatments, especially those
that are commonly taken amongst individuals with COVID-19. It
has been seen here, for example, that between 1 in 10 and 2 in 5
of those hospitalised with COVID-19 were taking medicines
acting on the renin–angiotensin system in the month before their
hospital admission. The consequences of temporarily discontinu-
ing such treatments on cardiovascular risks and mortality remain
unknown11. Interestingly, corticosteroid use, recently shown to be
effective to treat COVID-1912, was consistently seen to be less
prevalent in patients hospitalised with COVID-19 compared to
those hospitalised with influenza across databases, as were alpha-
blockers which some have hypothesised to have a beneficial effect
in COVID-1913.
It should be noted that the characteristics of individuals with
COVID-19 have been described in this study at the particular
point in time of admission to hospital. While this is of particular
interest given its intrinsic link with healthcare utilisation, this
only provides a snapshot of the whole picture. Those testing
positive for COVID-19 in the community without progressing to
hospitalisation can be expected to be younger and with fewer
comorbidities than those hospitalised9,14, while those progres-
sing to intensive care can be expected to be older and in worse
general health3,15. In addition, those being referred to or
admitted to intensive care also seem more likely to be male3,15.
Admission to hospital (and intensive care) is also influenced by a
range of supply-side factors, such as availability of beds and
criteria for admission, and so the characteristics of those
hospitalised do not necessarily only reflect the characteristics
accompanying severe illness. These factors likely explain some of
the heterogeneity seen in those hospitalised with COVID-19 in
this study. Geographic variation in populations and transmission
dynamics can also be expected to explain the variation across
sites. This particularly relevant for patients from South Korea,
where given the management of COVID-19 in the country, the
patient population is more closely reflective of those infected
during early outbreaks.
Study limitations. The study was based on routinely collected
data and so, as always, data quality issues must be considered. For
instance, individuals were considered as having COVID-19 at the
time of hospitalisation only if they had a test result or diagnosis
indicating the disease, which will have led to the omission of
individuals who can be suspected to have had the disease but
lacking confirmation of it. Medical conditions may have been
underestimated as they were based on the presence of condition
codes, with the absence of such a record taken to indicate the
absence of disease. Meanwhile, medication records indicate that
an individual was prescribed or dispensed a particular drug, but
this does not necessarily mean that an individual took the drug as
originally prescribed or dispensed. Our study could be subject to
exposure misclassification with false positives if a patient had a
medication dispensing event but did not ingest the drug, but may
also be subject to false negatives for non-adherent patients who
continued their medication beyond the days of supply due to
stockpiling. Medication use estimates based on the data collected
at the time of hospitalization is particularly sensitive to mis-
classification, and may conflate baseline concomitant drug history
with immediate treatment upon admission.
Time periods were inclusive of the day of hospitalisation, so
that information on conditions captured on the day of
hospitalisation and medication use up to and including the day
of hospitalisation were captured. Other time frames could though
have been considered for information prior to hospitalisation.
Moreover, outcomes after the index date have not been
summarised as these were outside the scope of this particular
study. Associations between particular patient characteristics and
the risks of hospitalisation and outcomes following hospitalisa-
tion were also beyond the scope of this study, and remain an area
for further research.
Comparisons of individuals hospitalised with COVID-19 with
individuals previously hospitalised with influenza have limita-
tions. In particular, observed differences may be explained by
changes in clinical practice or data capture procedures over time,
rather than by differences in the individuals themselves. This is
likely particularly relevant for comparisons of medication use
which, in particular, can be expected to vary over time. Changes
in practice in response to the COVID-19 pandemic, such as
referrals which may not be observed in our data and thresholds
for hospitalisation, also may in part explain some of the observed
differences in patient profiles.
Interpretation. Rates of comorbidities and medication use are
high among individuals hospitalised with COVID-19. Those
individuals hospitalised with COVID-19 do not, however, appear
to be in worse general health than those typically hospitalised
with influenza. Indeed, in many cases, individuals hospitalised
Table 2 (continued)
CUIMC
(n: 1759)
HIRA
(n: 7341)
HM (n: 2078) PHD
(n: 5257)
SIDIAP (n:
16,347)
UC HDC
(n: 769)
VA OMOP
(n: 577)
Day of hospitalisation 9.9% 2.4% <0.5% 13.1% 4.7% 25.4% 14.6%
Lipid-modifying agents
Year up to, and including day
of, hospitalisation
33.8% 18.4% – – 26.8% 41.7% 61.9%
30 days up to, and including
day of, hospitalisation
20.8% 15.5% – – 23.6% 36.4% 50.8%
Day of hospitalisation 18.7% 14.1% 5.4% 19.9% 23.0% 35.6% 43.8%
Study participants from HM and PHD were not required to have a year of prior history and so only medications at the time of hospitalisation are summarised.
CUIMC Columbia University Irving Medical Center, HIRA Health Insurance Review & Assessment, HM HM Hospitales, PHD Premier Healthcare Database, SIDIAP The Information System for Research in
Primary Care, UC HDC University of Colorado Health Data Compass, VA OMOP Department of Veterans Affairs.
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with COVID-19 were seen to be younger and healthier than
patients hospitalised with seasonal influenza. Patients hospitalised
for COVID-19 are also more likely to be male in comparison to
those hospitalised with influenza. Protecting those groups known
to be vulnerable to influenza is likely to be a useful starting point
to minimize the number of hospital admissions needed for
COVID-19, but such strategies may need to be broadened so as to
reflect the particular characteristics of individuals seen here to
have been hospitalised with COVID-19.
Methods
Study design. This is a cohort study based on routinely collected primary care and
hospital electronic health records (EHRs), hospital billing data, and insurance
claims data from the US, South Korea and Spain. The data sources used were
mapped to the Observational Medical Outcomes Partnership (OMOP) Common
Data Model (CDM)16. The open-science Observational Health Data Sciences and
Informatics (OHDSI) network maintains the OMOP CDM, and its members have
developed a wide range of tools to facilitate analyses of such mapped data17. Two
particular benefits of this approach were that contributing centres did not need to
share patient-level data and common analytical code could be applied across
databases.
Data sources. Data from the US, South Korea, and Spain underpinned the study.
EHR data from the US came from the Columbia University Irving Medical Center
(CUIMC), covering NewYork-Presbyterian Hospital/Columbia University Irving
Medical Center, University of Colorado Health Data Compass (UC HDC), which
includes the UCHealth System with data from 12 hospitals, and United States
Department of Veterans Affairs (VA OMOP), which includes 170 medical centres.
In addition, data from a US hospital billing system database came from the Premier
Hospital database (PHD). EHR data from Spain came from The Information
System for Research in Primary Care (SIDIAP), a primary care records database
that covers ~80% of the population of Catalonia, Spain18, and the inpatient care
database of HM Hospitales (HM), a hospital group which includes 15 general
hospitals from all over Spain, with detailed hospital admission information for
COVID-19 patients from March 1 to April 20, 2020. Data from South Korea came
from Health Insurance Review & Assessment (HIRA), a repository of national
claims data which is collected in the process of reimbursing healthcare providers19.
In addition, the analysis was also performed on US EHR data from Tufts-Clinical
Academic Research Enterprise Trust (CLARET), which covers Tufts Medical
Center (TMC), and the STAnford medicine Research data Repository (STARR-
OMOP), which includes data from Stanford Health Care20, and on data from the
Daegu Catholic University Medical Center, a teaching hospital in Daegu, South
Korea, covered by Federated E-health Big Data for Evidence Renovation Network
(FEEDER-NET). These latter sites are not reported here due to smaller study
populations, but the results are reported in the accompanying interactive website
(http://evidence.ohdsi.org/Covid19CharacterizationHospitalization/).
Each database was mapped to the OMOP CDM, which was developed as a
means of standardising the structure, content and semantics of observational
databases21. The OHDSI network has maintained and further developed this
common data model since 2014, developing tools to both facilitate the mapping of
source data to the OMOP CDM and analysing it once mapped. While the journey
of implementing the extract, transform, and load process varies across sites (given
factors such as infrastructure, size of the database, the complexity of the mapping,
and the technical expertise available), the destination is the same for each site; a
database which conforms to the requirements of the OMOP CDM. The mapping of
source codes to standard concepts is done using OMOP standardised vocabularies,
which are regularly updated22. In OHDSI studies, such as this one, data partners
run the same analysis package using a distributed network approach, where
analyses are run locally and only aggregated summary statistics are then shared.
OHDSI held a COVID-19 studyathon in March 2020, during which this study was
initiated. To note, the OMOP CDM has also been used to facilitate network
COVID-19 studies by the 4CE consortium, in which trajectories of laboratory test
measurements among COVID-19 patients were described23, and is being used by
the N3C consortium to help harmonise EHR data on COVID-19 patients24.
Study participants. Patients hospitalised between December 2019 and April 2020
with COVID-19 were identified on the basis of having a hospitalisation along with
a confirmatory diagnosis or test result of COVID-19 within a time window from
21 days prior to admission up to the end of their hospitalisation. This time window
was chosen so as to include those who had the diagnosis made prior to their
hospitalisation and allow for a delay in test results or diagnoses to be made or
recorded. Patients were also required to be aged 18 years or older at the time of
hospitalisation. The same algorithm was used to identify COVID-19 cases across
sites, except for CUIMC where the algorithm was adjusted to account for local
coding practice. The codes used to identify COVID-19 are described in more detail
in Supplementary Methods.
Analogous criteria were used for identifying individuals hospitalised with
influenza between September 2014 and April 2019, with individuals identified on
the basis of having a hospitalisation along with a confirmatory diagnosis or test
result of influenza within a time window from 21 days prior to admission up to the
end of their hospitalisation. For SIDIAP, influenza cases were only available up to
the end of 2017. An additional cohort of those hospitalised with influenza between
September 2009 and April 2010 was also identified. The motivation for this latter
group was that the 2009–2010 flu epidemic included many cases of A(H1N1)
pdm09 infection, which had different clinical characteristics and associated severity
compared to the seasonal flu. Each individual’s first hospitalisation with COVID-19
or a particular flu season was considered.
Except for the HM and Premier databases, individuals were required to have a
minimum of 365 days of prior observation time available for the primary analysis,
to allow for a comprehensive capture of baseline diagnoses and medications up to
their hospitalisation. Individuals’ observation period in the OMOP CDM reflects a
period during which any clinical event that happens to the patient is expected to be
recorded. The way this is operationalised does though depend on the type of source
data being used. For claims data, for example, observation periods are generally
inferred from the enrolment periods to a particular plan, while for EHR
observation periods generally begin at the time of interaction with the health
system. Consequently, as the requirement for prior observation time could exclude
persons with little prior healthcare utilisation or without sustained health
insurance, we also characterised cohorts without this restriction in a sensitivity
analysis. Given the nature of data collection, individuals in HM and Premier had
no prior observation time available and so no requirement for prior observation
time was imposed.
Patient features and data analysis. Age at hospitalisation and sex distributions
were summarised. Medication use was calculated over three time periods: (1) from
a year prior up to, and including, the day of hospitalisation, (2) from 30 days prior
up to, and including, the day of hospitalisation and (3) the day of hospitalisation.
Only the latter time period was reported for HM and Premier. Drug eras were
calculated to give the span of time when an individual is assumed to be exposed to
a particular active ingredient. These begin on the start date of the first drug
exposure and end on the observed end date if available, or were inferred (for
example, based on the number of days of supply). A persistence window of up to
30 days was permitted between two medication records for them to be considered
as part of the same drug era. Individual medications were categorised using
Anatomical Therapeutic Chemical (ATC) groupings. All drugs are reported in full
in a dedicated interactive website (see ‘Results’ section), but specific classes are
reported here based on recent interest due to their potential effects (positive or
negative) on COVID-19 susceptibility or severity: agents acting on the
renin–angiotensin system (including angiotensin-converting enzyme (ACE) inhi-
bitors and angiotensin II receptor blockers (ARBs)), antiepileptics, beta-blocking
agents, calcium channel blockers, diuretics, drugs for acid related disorders,
immunosuppressants, insulins, analogues and lipid-modifying agents (such as
statins). Prevalence of medication use for each time window was determined by the
proportion of persons who had at least one day during the time window over-
lapping with a drug era for each medication or drug class of interest. Conditions
were identified on the basis of SNOMED codes, with all descendent codes included.
Similarly, all recorded diagnoses are available for consultation in the accompanying
website, but a list of key conditions is reported here based on recent reports of
associations with COVID-19 infection or outcomes.
Age distributions in each cohort were plotted. The proportion of a cohort
having a particular characteristic was described, with the prevalence of all
medications and conditions captured in the databases depicted using Manhattan-
style plots. Standardised mean differences (SMD) were calculated when comparing
characteristics of study cohorts, with a SMD of above 0.1 generally considered to
indicate a meaningful difference in the prevalence of a covariate25. The SMDs for
all variables were plotted in Manhattan-style plots. In addition, the prevalence of
particular conditions or medications of interest among those hospitalised with
COVID-19 (Y axis) were compared to those hospitalised with influenza (X axis) in
scatter plots, with dots on the top-left indicating a higher prevalence among those
hospitalised with COVID-19 and dots on the bottom-right indicating a higher
prevalence among those hospitalised with influenza.
Ethical approval. All the data partners received Institutional Review Board (IRB)
approval or exemption. STARR-OMOP had approval from IRB Panel #8 (RB-
53248) registered to Leland Stanford Junior University under the Stanford Human
Research Protection Program (HRPP). The use of VA data was reviewed by the
Department of Veterans Affairs Central Institutional Review Board (IRB) and was
determined to meet the criteria for exemption under Exemption Category 4(3) and
approved the request for Waiver of HIPAA Authorization. The research was
approved by the Columbia University Institutional Review Board as an OHDSI
network study. The IRB number for use of HIRA data was AJIB-MED-EXP-20-
065. HM Hospitales and SIDIAP analyses were approved by the Clinical Research
Ethics Committee of the IDIAPJGol (project code: 20/070-PCV). The UC-HDC
data use was reviewed by Colorado Multi-Institutional Review Board (COMIRB)
and was determined to meet the criteria for exemption under Exemption Category
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-18849-z
8 NATURE COMMUNICATIONS |         (2020) 11:5009 | https://doi.org/10.1038/s41467-020-18849-z | www.nature.com/naturecommunications
4(3) and approved the request for Waiver of HIPAA Authorization (protocol # 20-
0730).
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The aggregated results set, that does not include patient-level health information, is
available via http://evidence.ohdsi.org/Covid19CharacterizationHospitalization/. Data
partners (Columbia University Irving Medical Center [CUIMC], Health Insurance
Review & Assessment [HIRA], HM Hospitales [HM], Premier Hospital database [PHD],
The Information System for Research in Primary Care [SIDIAP], United States
Department of Veterans Affairs [VA OMOP] and University of Colorado Health Data
Compass [UC HDC]) contributing to this study remain custodians of individual patient-
level health information.
Code availability
The analytic code used in the study has been made available at https://github.com/ohdsi-
studies/Covid19HospitalizationCharacterization26. This study package is run from R and
is a OHDSI CohortDiagnostics-type package27. This makes use of other OHDSI
packages, such as FeatureExtraction28, to extract patient characteristics for user-specified
cohorts in the common data model.
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